Cargando…
Medical Management of Parkinson’s Disease: Focus on Neuroprotection
Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease (PD) treatment is focused on drugs with neuroprotective properties...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131725/ https://www.ncbi.nlm.nih.gov/pubmed/22131943 http://dx.doi.org/10.2174/157015911795596577 |
_version_ | 1782207751418544128 |
---|---|
author | Boll, Marie-Catherine Alcaraz-Zubeldia, Mireya Rios, Camilo |
author_facet | Boll, Marie-Catherine Alcaraz-Zubeldia, Mireya Rios, Camilo |
author_sort | Boll, Marie-Catherine |
collection | PubMed |
description | Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease (PD) treatment is focused on drugs with neuroprotective properties in preclinical experiments and evidence-based efficacy in human subjects. To this date, neuroprotection has never been solidly proven in clinical trials but recent adequate markers and/or strategies to study and promote this important goal are described. A myriad of compounds with protective properties in cell cultures and animal models yield to few treatments in clinical practice. At present, markers of neuronal vitality, disease modifying effects and long term clinical stability are the elements searched for in clinical trials. This review highlights new strategies to monitor patients with PD. Currently, neuroprotection in subjects has not been solidly achieved for selegiline and pramipexole; however, a recent rasagiline trial design is showing new indications of disease course modifying effects. In neurological practice, it is of utmost importance to take into account the potential neuroprotection exerted by a treatment in conjunction with its symptomatic efficacy. |
format | Online Article Text |
id | pubmed-3131725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Bentham Science Publishers Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31317252011-12-01 Medical Management of Parkinson’s Disease: Focus on Neuroprotection Boll, Marie-Catherine Alcaraz-Zubeldia, Mireya Rios, Camilo Curr Neuropharmacol Article Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease (PD) treatment is focused on drugs with neuroprotective properties in preclinical experiments and evidence-based efficacy in human subjects. To this date, neuroprotection has never been solidly proven in clinical trials but recent adequate markers and/or strategies to study and promote this important goal are described. A myriad of compounds with protective properties in cell cultures and animal models yield to few treatments in clinical practice. At present, markers of neuronal vitality, disease modifying effects and long term clinical stability are the elements searched for in clinical trials. This review highlights new strategies to monitor patients with PD. Currently, neuroprotection in subjects has not been solidly achieved for selegiline and pramipexole; however, a recent rasagiline trial design is showing new indications of disease course modifying effects. In neurological practice, it is of utmost importance to take into account the potential neuroprotection exerted by a treatment in conjunction with its symptomatic efficacy. Bentham Science Publishers Ltd 2011-06 /pmc/articles/PMC3131725/ /pubmed/22131943 http://dx.doi.org/10.2174/157015911795596577 Text en © Bentham Science Publishers Ltd http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Boll, Marie-Catherine Alcaraz-Zubeldia, Mireya Rios, Camilo Medical Management of Parkinson’s Disease: Focus on Neuroprotection |
title | Medical Management of Parkinson’s Disease: Focus on Neuroprotection |
title_full | Medical Management of Parkinson’s Disease: Focus on Neuroprotection |
title_fullStr | Medical Management of Parkinson’s Disease: Focus on Neuroprotection |
title_full_unstemmed | Medical Management of Parkinson’s Disease: Focus on Neuroprotection |
title_short | Medical Management of Parkinson’s Disease: Focus on Neuroprotection |
title_sort | medical management of parkinson’s disease: focus on neuroprotection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131725/ https://www.ncbi.nlm.nih.gov/pubmed/22131943 http://dx.doi.org/10.2174/157015911795596577 |
work_keys_str_mv | AT bollmariecatherine medicalmanagementofparkinsonsdiseasefocusonneuroprotection AT alcarazzubeldiamireya medicalmanagementofparkinsonsdiseasefocusonneuroprotection AT rioscamilo medicalmanagementofparkinsonsdiseasefocusonneuroprotection |